// App-Quantinova.ai

4818 : Tolfenamic acid and curcumin treatment induces pancreatic cancer cell growth inhibition via suppressing Sp1 expression, NF-kB translocation to nucleus

Researchers

Presenter

  • Riyaz M. Basha

Principal Investigators

  • Sarah F. Connelly

  • Ganji Purnachandra

  • Umesh T. Sankpal

  • Hassaan Patel

  • Jamboor K. Vishwanatha

  • Sagar Shelake

  • Leslie Tabor-Simecka

  • Mamoru Shoji

  • Jerry Simecka W. Simecka

  • Bassel El-Rayes

Medical Centers

  • University of North Texas - Health Science Center, Fort Worth, TX

  • MD Anderson Cancer Center, Pearland, TX

  • Emory University, Atlanta, GA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Pancreatic cancer

  • Cardiotoxicity

  • Solid malignancies

  • Pancreatic and cerebellar agenesis

Biomarkers

  • Proto-oncogene tyrosine-protein kinase ROS

  • Melanoma-inhibitory activity

Drug/Treatment

  • Flocur

  • Celecoxib

  • ALT-210

  • Ibuprofen

  • liposomal curcumin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved